About

Mahzi, which is based on the Greek word for “Together”, aims to unite patient and family groups, academic researchers, other industry members, and our internal team of experts to develop therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders.

Our team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases.

Team

Yael Weiss

Yael Weiss, MD, PhD

Chief Executive Officer
headshotsAB

Allyson Berent, DVM, DACVIM

Chief Development Officer
headshotsCTO

Christina Theodore-Oklota, PhD

VP, Clinical Outcomes Research
headshotsER

Emily Radomile

Executive Director, Program Management & Clinical Operations
Jennifer Panagoulias

Jennifer Panagoulias

Chief Regulatory & Compliance Officer
Rob Anstey

Rob Anstey

Chief Financial Officer
Sean Cullen

Sean Cullen

VP, Technical Operations
Steve Jungles

Steve Jungles

Chief Technical Operations Officer

Board of Directors

1516239180519

Shalini Sharp

Chair
Yael Weiss

Yael Weiss, MD, PhD

CEO | Mahzi
csamuels_detail

Camille Samuels

Venrock
1529308407025

Marten Steen, MD

HealthCap
1516339690165

Priyanka Belawat, PhD

HBM (observer)
1517774449995

Luc Dochez

Droia (observer)
headshotsJM

John Maraganore

Senior Advisor (observer)

Investors

venrock

Venrock

healthcap

HealthCap

DROIAventures

Droia Ventures

logo@2x

HBM Partners

logo.5

ArrowMark Partners

logo-ultragenyx

Ultragenyx